Activated ADAM10 targeting antibody 1H5 suppresses NOTCH-driven glioma progenitors
Background: High-grade gliomas (HGGs) remain associated with high morbidity, mortality, and invariable recurrence after neurosurgical resection and chemoradiation. A major contributor to treatment failure is a population of stem-like glioma progenitor cells (GPCs) that depend on NOTCH-signaling for self-renewal and survival; clinical attempts to inhibit NOTCH with {gamma}-secretase inhibitors…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
